Rating: Neutral (Hold) | Target Price Range: RMB 197–230 | Current Price: RMB 231.20 (as of 2026-11-11 close) | Margin of Safety: approx. −15% | Time Horizon: 12–18 months
Rating note: Neutral = the current price is near the upper edge of the base-case fair value range (RMB 197–230), fully pricing in two years of high growth per sell-side consensus; quality is excellent but the risk/reward is slightly negative. We recommend waiting for evidence upgrades or a price pullback before reassessing entry. Market cap basis: RMB 231.20 × 201.12 million shares ≈ RMB 46.498 billion.
Accotest is the undisputed domestic leader in analog/mixed-signal/power semiconductor test equipment (ATE), with over 8,000 cumulative installations worldwide and a 74%–75% gross margin that ranks among the highest globally. With the current AI/HBM test supercycle overlapping with OSAT capacity expansion and import substitution, the company's order and earnings delivery is real: revenue for the first three quarters of 2026 was RMB 1.353 billion (+44.0%), adjusted (ex-non-recurring) net profit RMB 505 million (+46.9%), contract liabilities +142% vs. the beginning of the year, and order visibility (per management) through March 2027. However, at the current price of RMB 231.20, the stock trades at about 71x adjusted TTM earnings and about 49x our own 2027E adjusted earnings, already fully pricing in sell-side consensus high growth for 2026–2027. This report's base-case fair value is RMB 197–230 (midpoint RMB 213); the current price is about 9% above the midpoint, the margin of safety is negative, and the probability-weighted expected value across three scenarios is about RMB 215 (−7%). There are three core constraints: weakening cash content of earnings (OCF/adjusted profit 0.39, annualized receivables/revenue rising to about 46%), unproven high-end volume ramp of the SoC second growth curve (STS8600), and the risk of a test-equipment cycle peaking in 2027–2028 alongside continued share reductions by the controlling shareholder. Conclusion: a good company at an expensive price. Wait for the 2026 annual report to validate order-to-revenue conversion, confirmation of volume orders for the 8600, or a pullback below RMB 200 before reassessing; a break below RMB 197 (base-case floor) and above RMB 318 (bull-case floor) are the two-way tracking triggers.
Order signals are real and corroborated by multiple sources: contract liabilities of RMB 188 million (+142% vs. beginning of year), doubling of raw material stockpiling in inventory, and Q3 standalone adjusted profit +54.9% accelerating. But two caveats apply: First, the absolute contract liabilities equal only about 0.31x of Q3 standalone revenue; converting to backlog (at a 30–50% prepayment ratio, roughly RMB 400–600 million), this covers less than half of the revenue needed for 2027H1 (about RMB 960 million), and the company has not disclosed total backlog; second, the core growth driver of the industry's +55% in 2025 was SoC/memory testers (Advantest/Teradyne's home turf), while the company's core business is analog/power, with SoC revenue only starting in 2026 — extrapolating industry boom requires a discount. The divergence between Q3 standalone net profit of only +22.1% (dragged by fair value) and adjusted +54.9% should also be presented side by side.
Refutation conditions: 2026 annual report Q4 standalone revenue < RMB 529 million (YoY <+30%) or full-year adjusted profit < RMB 650 million; annual report contract liabilities < RMB 120 million with a significant lengthening of inventory turnover days.
Confirmed at the fact level: OCF/adjusted net profit fell from the 0.55–0.62 plateau of FY2024–2025 to 0.39 for the first three quarters (OCF/net profit 0.30, with the denominator including RMB 163 million in fair value gains); annualized receivables/revenue ratio rose step by step from 36.0% → 41.1% → about 46%; adjusted/reported profit fell to 77.7%. For fairness, qualitatively: cash received from sales was RMB 1.380 billion (+59.2%) with a cash collection ratio of 1.02 — absolute collections are improving; the cash gap is mainly due to strategic stockpiling (cash paid for goods purchases RMB 700 million, +97%) and receivables expansion — working capital consumption typical of an upcycle, with no evidence yet of receivables aging deterioration. The risk lies at the inflection point: if revenue decelerates in 2027 while receivables/inventory grow on inertia, "high profit growth + deteriorating cash flow" will become the trigger for a valuation downgrade.
Refutation conditions: Annual report OCF/adjusted profit < 0.35, or significant deterioration in the proportion of receivables aged over 1 year and impairment provisions; a reverse repair signal would be receivables growth falling back within revenue growth.
The "0 to 1" of the second curve has already happened (the 8300 platform carries SoC revenue and has achieved orders and installations; external bank timelines also point to the 8600 commercializing in 2027), but the 8600 high-end platform is still in customer validation and has not contributed volume revenue; the convertible bond proceeds arrived on 6-29, only 1 day before the special report period-end — its "zero investment spent" is a timing artifact and does not constitute evidence of execution lag. In valuation structure terms, this report estimates EPV (zero-growth sustainable cash flow value) at about RMB 26/share (sensitivity range RMB 21–33), with an asset value floor of about RMB 29/share — about 89% of the current price is a growth option, whose realization depends on 8600 volume and a rising SoC revenue share; the 2026 annual report's product-level breakdown will be the first quantitative validation point.
Refutation conditions: No quantitative disclosure of SoC-related revenue or no volume orders for the 8600 by the 2027 interim report; annual report fundraising investment progress remains near zero with no feasibility explanation.
The current price corresponds to about 49x our 2027E adjusted earnings and 38.9x consensus 2027E EPS, a premium of 45%–90% over the global duopoly (forward about 26.5–31x), about a 25% premium over A-share Changchuan (forward about 51x) on an adjusted basis, and roughly at parity on a reported-profit basis. Sell-side target prices (JPM 390 / Citi 430 / consensus 385 yuan) approach the upper edge of this report's bull-case range (RMB 318–376) — the disagreement is essentially about scenario probabilities, not arithmetic: sell-side pricing implies 2027 revenue +44% and a smooth 8600 ramp, while this report assumes +27% given order visibility only through 2027-03 and OSAT capacity landing in 2027–28. Two honest caveats: First, under two-week swings of ±35%, comparisons against a static fair value range (±8% width) carry high noise, limiting the confidence of this conclusion; second, if the RMB 749 million convertible bond triggers a downward conversion-price revision and converts in 2027, potential dilution is about 1.1% of share capital, with a small possible downward revision to the forward EPS denominator.
Refutation conditions: Advantest/Teradyne guidance cuts or North American cloud capex downgrades (industry denominator reversal); a reverse signal (refuting this thesis's "expensive" judgment) would be Q4 order-to-revenue conversion exceeding expectations + 8600 volume orders landing.
Quantified, the impact is limited: the unlock value at the current price is about RMB 510 million, only about 0.3 days of turnover (30-day average daily turnover RMB 1.62 billion), and the transferees' floating loss of 29.7% weakens selling motivation; the controlling shareholder has cashed out about 2.1% of share capital cumulatively over 18 months (about 1.0% reduction in Nov/Dec 2025 + 1.1% block trade in Sep 2026). Whether the no-actual-controller status (since 2026-03) is the norm among STAR Market equipment companies — this report has no comparative evidence and does not count it as a specific negative for now. RMB 250 (buyback cap) — RMB 328.94 (institutional transfer price) — RMB 362 (insider cost basis) form a multi-point ownership reference. Directional judgment: disturbances skew negative but do not break the thesis.
Refutation conditions: New reduction plans by the controlling shareholder/insiders, or concentrated selling of over 500,000 shares within 20 trading days after the 2027-03 unlock.
| Metric (RMB 100M) | FY2023 | FY2024 | FY2025 | 2026Q1-3 | 2026Q3 standalone |
|---|---|---|---|---|---|
| Revenue | 6.91 | 9.05 | 13.46 | 13.53 | 6.14 |
| Revenue YoY | −35.5% | +31.0% | +48.7% | +44.0% | +51.7% |
| Net profit attributable to parent | 2.52 | 3.34 | 5.36 | 6.50 | 2.33 |
| Adjusted net profit | 2.53 | 3.40 | 4.92 | 5.05 | 2.62 |
| Gross margin | 71.19% | 73.31% | 73.81% | 74.89% | 75.12% |
| Net margin | 36.4% | 36.9% | 39.8% | 48.0% (incl. fair value) | 38.0% |
| Operating cash flow | 3.21 | 1.88 | 3.04 | 1.97 | — |
| Free cash flow (OCF−CapEx) | 2.96 | 1.57 | 2.38 | 1.00 | — |
| Capital expenditure | 0.25 | 0.31 | 0.66 | 0.97 (+239%) | — |
| R&D expense (fully expensed) | 1.32 | 1.72 | 2.66 | 3.03 (+66.4%) | — |
Balance sheet stock (as of 2026-09-30): cash + trading financial assets RMB 2.776 billion; interest-bearing debt RMB 716 million (including convertible bonds of RMB 690 million); net cash about RMB 2.060 billion; plus RMB 3.702 billion in other equity instrument investments (Sienol Integration, etc., with mark-to-market gains recorded in OCI, not the income statement); contract liabilities RMB 188 million, inventory RMB 540 million, accounts receivable RMB 829 million; debt-to-asset ratio 19.31%. The company is in a net-cash position with a deeply negative net debt/EBITDA and no leverage risk.
Reasons for metric changes (items with YoY ≥ ±20%, all per company disclosure): High revenue growth — "recovery of prosperity in the semiconductor industry and improvement in the company's operational efficiency, driving order growth" and "increase in market demand"; inventory +80.4% — "increased stockpiling, supply chain switching, and future order assurance needs... strategic stockpiling and delivery assurance attributes"; receivables +49.8% — "increase in operating revenue, with accounts receivable increasing correspondingly" (rising proportion not explained); contract liabilities +142% — "increase in orders, with corresponding increase in advance receipts"; CapEx +239% — production line expansion and SoC R&D equipment investment; OCF improvement — "increased revenue and higher collections from sales compared to the same period last year" (note: FY2025 cash inflows included government subsidies cash of RMB 64 million, vs. only RMB 4 million in the prior year).
2026Q3 quick commentary: Q3 standalone revenue of RMB 614 million (+51.7%) set a single-quarter record, with adjusted profit of RMB 262 million (+54.9%) accelerating; gross margin of 75.12% (+1.34pct) validates the shift in product mix (rising share of the 8300/8600 series); the gap between single-quarter reported profit growth of only +22.1% comes almost entirely from financial asset fair value turning negative (−RMB 36 million) — the divergence between reported and operating profit is the single most important piece of information this quarter, and earnings delivery should be assessed on the adjusted basis. On the balance sheet, contract liabilities/inventory/receivables all jumped in tandem, pointing to a buildup for 2027H1 deliveries; the cost is the first-three-quarters OCF/adjusted profit falling to 0.39. The market reaction (continued pullback after the 10-28 disclosure) shows that at 58–71x valuations, the market no longer pays for "revenue beats" but prices on "earnings quality and 2027 visibility."
Model in brief: An asset-light, order-driven semiconductor back-end test equipment (ATE) systems developer and manufacturer—core processes in-house, mature processes outsourced, primarily direct sales. Revenue is dominated by one-time equipment sales, with the installed base driving recurring parts/services repurchases (parts account for 11.4% of main revenue). Customers are OSAT/IDM/fabless firms (including STMicroelectronics, onsemi, and Nexperia); the top five customers account for 40.12% and the largest 10.97%. Asset-light characteristics are clear: intangibles + goodwill are about 1.2% of total assets, with low CapEx intensity (FY2024 CapEx/D&A of 1.04).
Cash content of earnings: OCF/deducted net profit was FY2023 1.27 (strong collections in the downturn) → FY2024 0.55 → FY2025 0.62 → 0.39 for the first three quarters of 2026; FCF/attributable net profit went 1.18→0.47→0.44→0.15. The long-term average (OCF/deducted net profit of roughly 0.55–0.62 over the past four years) is acceptable, but the trend is downward and already below the 0.5 tier under the 0.8 warning line—the main cause is receivables + inventory absorption during the upcycle (receivables + inventory total RMB 1.370 billion = 101% of nine-month revenue); each additional yuan of revenue ties up roughly 0.5 yuan of working capital. Recurring earnings test: the deducted/attributable ratio fell from about 100% in FY2023–24 to 77.7% in the first three quarters—RMB 163 million of fair value gains (holdings in Sieno Integrated shares and fund asset-management plans) inflated headline profit, and the company has not disclosed arrangements regarding the sustainability of these items; government subsidies also warrant attention (in FY2025 other income, VAT refund-upon-collection plunged 67% without explanation, and new deferred income of RMB 58 million was recorded).
Return on capital: ROIC was about 7.5% in FY2023 → about 9.3% in FY2024 → about 13.1% in FY2025—already above WACC (roughly 9–10%) in the upcycle, but not yet at the 15% strong-moat threshold; after convertible bonds are funded in 2026, the denominator expands and ROIC will be diluted; recovery depends on SoC high-end product ramp. CapEx quality: FY2025 CapEx/D&A of 1.9 and CapEx of RMB 97 million in the first three quarters of 2026 (+239%), directed toward capacity expansion and R&D equipment; the company has not disclosed a maintenance/growth split; combined with the convertible bond proceeds (RMB 739 million for in-house ASIC test system development), the current phase is judged to be on an upswing of growth investment, and the maintenance investment floor cannot be determined. Moat and red flags: moat = installed base (8,000+ units forming a positive cycle of parts/services/software libraries) + customer certification barriers + 19.7% R&D intensity; red flags = weakening cash content of profit (as above), rising share of fair value gains in attributable profit, and moderately high concentration of top five customers at 40%.
Consistency of words and deeds: pragmatic; favors qualitative statements, no quantitative guidance. The FY2023 annual operating plan (stabilize the 8200 base, build the 8300 ecosystem, advance 8600 board development) → FY2024 revenue +31%, above industry growth, with 8300 in volume installation—delivered. The FY2024 plan (launch in-house ASIC test system, build a second production line in Malaysia) → June 2026 convertible bond of RMB 749 million funded toward the ASIC project, FY2025 overseas revenue +65.2%—in progress/mostly delivered. The FY2025 annual report cited WSTS/SEMI industry forecasts without giving its own quantitative guidance; the first three quarters of 2026 saw deducted net profit +46.9%, outperforming industry forecasts. No record of missed high-profile projections across three years.
Shareholder friendliness: neutral to friendly. Payout ratio FY2023 42.4% → FY2024 30.4% → FY2025 30.1% (RMB 161 million plus 4.8 bonus shares per 10 shares); in 2024, RMB 14.99 million of buybacks for equity incentives; in November 2026, a newly proposed buyback of RMB 50–100 million. On financing: 2020 IPO net proceeds of RMB 1.512 billion and 2026 convertible bonds of RMB 749 million—about RMB 2.26 billion raised since listing vs. cumulative dividends of about RMB 370 million over six years—a normal profile for an equipment company in a growth investment phase, not dilutive, but not a high-dividend stock either.
Risk signals: (1) On March 1, 2026, the concert-party agreement among the four founders expired without renewal, and the company became one with no de facto controlling shareholder—weakened coordination mechanism for major decisions; (2) intensive selling at the controlling shareholder level: China Times Yuanwang reduced holdings by 5.283 million shares in 2025, and Tianjin Xinhua sold 1.10% of share capital via negotiated block transfer in September 2026 for RMB 727 million (stake reduced to 24.31%); (3) Chairman and Board Secretary Sun Qiang's annual salary of RMB 4.06 million, plus the resignation in August of the securities affairs representative and subsequent re-hiring—personnel and governance signals warrant continued monitoring. Offsets: core technical staff member Liu Huipeng bought about RMB 10.14 million of shares with his own money at an average price of RMB 362 (now down about 36% on paper), and the chairman proposed buybacks at low levels.
| Segment (FY2025, share of main revenue) | Revenue share | Gross margin | YoY | Business logic in one line |
|---|---|---|---|---|
| Test systems (equipment) | 88.6% | 73.97% | +45.69% | STS8200/8300/8600 system sales; main profit engine (88.8% of main-business gross profit) |
| Test system parts | 11.4% | 72.55% | +77.16% | Repurchases from the installed base; faster growth than equipment, less cyclical |
| Domestic | 93.1% | 73.54% | +47.61% | Main battleground of domestic substitution (OSAT/IDM/fabless) |
| Overseas | 6.9% | 77.42% | +65.23% | Supply chains of ST/onsemi/Nexperia; higher gross margin, high elasticity |
Profit engine: test systems (revenue share 88.6% × gross margin 73.97% ≈ 88.8% of main-business gross profit)—the segment and profit structures are highly coincident; the company is in substance a single-business company. Gross margin structure differences are small (equipment vs. parts only 1.4pct, domestic vs. overseas 3.9pct); the real structural difference lies in platform generation and customer type, not in the disclosed segment split: the annual report does not break down revenue by 8200/8300/8600 platform or by analog/power/SoC application—and this is precisely the key gap for judging second-curve progress; if the FY2026 annual report quantifies SoC/digital test revenue by product line for the first time, that would be the direct basis for either a valuation re-rating or a downgrade. The overseas gross margin being 3.9pct higher reflects international customers' bargaining environment and product mix differences; going overseas (localized production line in Malaysia) is a medium-term variable for gross margin structure improvement.
Accounting red flags: (1) Receivables growth has significantly exceeded revenue growth for two consecutive years (FY2025 +69.95% vs. +48.72%; first three quarters of 2026 +49.8% vs. +44.0%); the receivables/revenue ratio has risen continuously from 36.0%→41.1%→about 46% (annualized); the company only explained "revenue growth" and did not explain the rising ratio—moderate concern; (2) FY2025 operating cash flow was supported by RMB 64 million of government subsidy cash received (vs. RMB 4 million the prior year), plus RMB 58 million of asset-related subsidies booked to deferred income—after excluding these, OCF quality is diminished—moderate concern; (3) profit is sensitive to fair value of financial assets: +RMB 163 million in the first three quarters (23% of total profit), −RMB 36 million in Q3 alone; the Sieno Integrated position of RMB 3.702 billion (48.3% of net assets) will continue to amplify swings in attributable profit and net assets—low concern (transparent treatment, not concealed).
Cross-period consistency: (1) OCF/attributable profit 1.28→0.56→0.57→0.30: management's explanations (increased collections/increased inventory stocking) are consistent with the account movements, but the systematic decline in cash content was not discussed; (2) the receivables/revenue ratio has risen continuously: the company did not explain; (3) deducted/attributable profit 100.6%→101.8%→91.8%→77.7%: the rising share of investment income, with the company not explaining the change in basis.
Conclusion: No typical earnings-management tricks found (no goodwill, no capitalized R&D, intangibles only 1.2% of assets); the statements are clean. However, the combination of "rising receivables ratio + fair value gains inflating headline profit + OCF dependent on subsidies" means profit quality on the attributable basis was systematically overstated by one notch in 2026; tracking should use the dual lens of deducted profit plus cash flow.
Current market data: price RMB 231.20 (close on 2026-11-11), market cap RMB 46.498 billion. PE-TTM 58.2x (attributable) / 71.2x (deducted), PB 6.07x, PS-TTM 26.4x. Historical percentiles (computed in this report): PE-TTM at the 20th percentile over 1 year, 52nd over 3 years, 64th over 5 years; PB at the 14th percentile over 1 year; total market cap at the 90th percentile over 5 years / 93rd over 10 years—percentiles are for reference only: the extreme 2026 market move (52-week range RMB 111–543) distorts short-cycle percentiles, and earnings are at a cyclical upswing high with genuinely strong deducted-profit growth; mechanical percentiles do not constitute a verdict on richness.
Peer comparison (TTM basis, mid-November 2026):
| Company | Market cap (RMB bn) | PE-TTM | Forward PE (2026E/2027E) | Latest revenue growth | Gross margin | ROE |
|---|---|---|---|---|---|---|
| Accotest (Huafeng) | 4.65 | 58.2 (deducted 71.2) | 51.4 (consensus attributable) / 48.9 (own 2027E deducted) | +44.0% (9M26) | 74.9% | FY2025 weighted about 13–14% |
| Changchuan Technology | 12.68 | 56.8 | about 50.8 (2026E) | +57.3% (9M26) | 55.8% | 33.2% (FY2025) |
| Advantest | about 94.81 | 39.6 | about 30.7 (guidance basis) | +44.7% (FY2025) | N/A (operating margin 44.2%) | about 47% (FY2025) |
| Teradyne | about 28.22 | 30.8 | about 26.5 (2026E) | +70% (Q3'26 single quarter) | about 59% | 19.7% (FY2025) |
Market-implied expectations: the current price = 2027E consensus EPS of RMB 5.95 × 38.9x. Two-way demand-side test: the side that supports it—order visibility to March 2027, OSAT capex +117% in 2026 transmitting to equipment purchases, 8300 SoC already installed, and global tester market forecasts adding another 30–40% over 2026–2028; the side that does not—the company's 2025 revenue comes almost entirely from analog/power (exposure to the AI testing battleground near zero at the start), no contract coverage for full-year 2027 orders, and the sell-side assumption of +44% 2027 revenue requires the 8600 to jump straight from qualification to volume ramp. This report takes the middle-to-conservative view: 2026E revenue RMB 1.92–2.02 billion (+43–50%), deducted profit RMB 710–745 million; 2027E revenue RMB 2.45–2.55 billion (+25–31%), deducted profit RMB 920–990 million—the current price requires the company to deliver about RMB 1.16–1.2 billion of profit in 2027 (backed out from comparable forward multiples), while this report's own estimate is RMB 940 million–1.01 billion; two years of consensus high growth have already been priced in.
Three-tier value (EPV): asset value floor of about RMB 29/share (net cash RMB 2.06 billion + investment portfolio at a 30% discount, conservative basis); EPV (zero-growth sustainable FCFE per share ÷ Ke) of about RMB 26/share—normalized base is 2026E deducted profit of RMB 727 million × cash conversion 0.72 (historical OCF/deducted profit 0.55–0.62; midpoint of 0.65–0.80 after excluding growth-related working capital absorption), Ke 10% (sensitivity range: 0.65 × Ke 11% → RMB 21; 0.80 × Ke 9% → RMB 33). About 89% of the current price is a growth option—this is a typical high-growth pricing structure, not proof of overvaluation; whether it should be paid depends on the scenario: the core underpinnings of the growth option (8600 / AI testing / domestic substitution penetration) are still in the qualification stage, which determines the width of the odds distribution at the current price.
Three scenarios and odds (12–18 months; fair value ranges are nominal values at 2027/2028 exit):
| Scenario | Probability | Fair range | vs. current price | Decisive factor |
|---|---|---|---|---|
| Bear | 25% | RMB 73–98 | −58% to −68% | 2027–28 cyclical peak (a 2023-style −35% revenue decline repeating) + price competition; deducted profit falls back to RMB 400–510 million, exit at 27–31x (anchor: company's 10-year PE trough of 27.9x) |
| Base | 50% | RMB 197–230 | −15% to 0% | 2027 growth of +25–31% delivered; deducted profit RMB 920–990 million × 38–42x (anchor: midpoint-to-lower of global duopoly forward 26.5–31x and A-share Changchuan forward about 51x) + net cash and investments |
| Bull | 25% | RMB 318–376 | +38% to +63% | 8600/SoC ramp: 2028E revenue RMB 3.35 billion, deducted profit RMB 1.357 billion × 45–50x (anchor: Changchuan TTM 56.8x discounted for execution risk), approaching the sell-side target range |
Probability-weighted expectation about RMB 215 (−7%); margin of safety (base-case fair floor of RMB 197 vs. current price) about −15%. Odds slightly negative, wide distribution: the current price sits at the top edge of the base-case range; the downside bear-case space (−58% to −68%) exceeds the upside bull-case (+38% to +63%) in magnitude, and the bear case's probability is not low (25%). Rationale for the base-case exit multiple of 38–42x: below the company's current forward multiple (48.9x)—not justified by the current price's own multiple; above the global duopoly (26.5–31x)—retaining a moderate premium for A-share liquidity and the scarcity of domestic substitution; below Changchuan (about 51x)—a discount reserved for the unproven 8600.
Conclusion: mildly overvalued (fair but rich). Quality and price considered separately: quality is excellent (gross margin 74%+, ROIC 13.1% and rising, net cash RMB 2.06 billion plus an investment portfolio of RMB 3.7 billion, genuine orders); on price, the current level already embeds two years of consensus high growth; the base-case fair value is RMB 197–230, with the current price about 9% above the midpoint—"expensive to a limited degree but with no margin of safety." This judgment holds provided there is no cyclical hard landing in 2027; if Q4 order conversion and 8600 orders both materialize, this report's base case will shift toward the bull case.
Industry size: The global semiconductor test equipment market (SEMI basis, including testers/handlers/probers) was approximately USD 7.55 billion in 2024, with 2025 actual billings up +55% YoY (estimated at ~USD 11.7 billion, driven by AI/HBM); within testers specifically, Advantest forecasts the 2026 SoC + memory tester market at USD 13–14.5 billion, a record high (up 30–40% from the ~USD 9–10 billion estimated for 2025); Jefferies projects the test market growing from ~USD 9 billion in 2025 to USD 25 billion by 2030 (implied CAGR ~22.7%). China market: ~USD 2.5 billion in 2024, roughly 35% of the global total (SEMI, cited via brokerages); estimated on a global tester basis, China's tester market in 2025 is ~RMB 22.5 billion (our estimate). Note the basis divergence: third-party estimates of the "test equipment/tester" market size can differ by up to 50% (depending on whether handlers/probers are included); always specify the basis when citing.
Value chain and profit distribution: Upstream comprises FPGAs, high-speed ADCs/DACs, precision analog components, and PCB structural parts (raw materials account for 85.6% of Huafeng's operating costs); midstream ATE systems (Advantest/Teradyne/Huafeng/Changchuan/Liantong) carry gross margins of 55–74%, the richest profit pool in the value chain; downstream comprises IDMs/fabless designers/foundries/OSAT packaging & test houses (JCET/Tongfu/Huatian/WeTest). Huafeng sits in the midstream system-integration layer, where gross profit is heavily retained at the equipment end (Huafeng's gross margin is 73.8%, vs. JCET's 2025 weighted ROE of only 5.56% in the packaging/test segment); it wields relatively strong bargaining power downstream (dominant domestic position in analog testers + 8,000 installed units + reasonably diversified customers) and strong bargaining power upstream over generic components, but high-end FPGAs/high-speed ADCs depend on US-origin suppliers — the company's 2025 annual report lists "short-term supply assurance, mid-term reduction of controlled materials, long-term self-sufficiency" as a main line and has introduced domestic suppliers, direct evidence of the impact of export-control spillover. Under the fabless model, the tester model selected at the design-validation stage often determines the volume-production model (per Advantest's investor guide), making tester share extremely sticky.
Supply-demand and competitive landscape: A global duopoly-dominated market — Advantest held 58% of the global tester market in CY2024 (company self-estimate), with CR2 (including Teradyne) at ~80%; domestic players include Huafeng, Changchuan (2025 revenue RMB 5.29 billion, 3.9x Huafeng's scale), Liantong Technology, Jingzhida, Jinhaitong, and others. Demand side: explosive AI/HPC chip and HBM test demand (rising complexity increases test insertions, with "technology-driven buying + capacity-driven buying" compounding), mature-node analog/power capacity expansion (China IC output Jan–Feb 2026: 81.5 billion units, +12.4%), and packaging/test capacity buildouts (China's 2026 advanced packaging capex totals RMB 39.2 billion, +117%, SEMI basis as cited by media, unverified). Supply side: AI-related SoC/HBM testers are in shortage (Advantest raised guidance three times within 2026; FY2026 revenue guidance JPY 1,863.0 billion, +65%); the analog tester segment has ample domestic supply, with competition reasonably robust but no vicious price war (Huafeng's steadily rising gross margin corroborates). Entry barriers: multidisciplinary technology + long R&D cycles (Huafeng's R&D intensity of 19.7%), long customer qualification cycles, extremely high switching costs (changing tester models = rebuilding the customer's entire development/validation/production environment), and a virtuous cycle of installed base and software ecosystem. Substitution threat: none directly — testing is a mandatory step and insertions increase with advanced packaging (2.5D/3D); SLT/burn-in are complements.
Cyclicality and regulation: The cycle is in the upper-middle of an upswing — leading indicators: third-party test utilization (WeTest above 90% as of 2026-09), OSAT capex, duopoly guidance (Teradyne's Q4'26 guidance flattening sequentially is the first signal to watch), and Huafeng's contract liabilities/inventory. Cycle-top risk is accumulating into 2027–2028: the +117% OSAT capex in 2026 creates a very high base, with lines ramping en masse in 2027–28; front-loaded equipment orders mean a meaningful probability of demand payback and decline. Regulation: test equipment falls under ECCN 3B002; mainstream analog/mixed-signal/SoC digital testers as complete units are outside the scope of US license requirements for China (Han Kun interpretation, 2024-03), but controls spill over into US-origin components inside equipment and Entity List expansion (BIS added 131 Chinese entities in 2025); localization policy (Big Fund/STAR Market financing support) provides institutional tailwind for share gains — directionally neutral-to-positive, with tail risk in upstream supply cutoff.
Quantified demand-inflection chain: Valid but layered — a clear exogenous inflection exists at the industry level: AI compute chips + HBM cause a step-change in test demand (2025 global semiconductor sales of USD 795.6 billion, +26.2%; 2026E ~USD 975 billion; 2026 SoC + memory tester market +30–40%); per-unit value steps up: analog testers (Huafeng ASP ~RMB 830,000 per set) → mid-to-high-end SoC testers (millions of RMB). At the company level, localization penetration is layered on top: domestic substitution rates for analog/discrete-device testers already reached 81%/84% in 2022 (GuanYan TianXia basis, third-hand, unverified) — the substitution dividend of Huafeng's core business is largely realized; SoC/memory tester localization is below 5% (broker basis, low reliability), the next battleground. Transmission chain: domestic GPU/CPU/ASIC shipment ramp × (per-chip AI SoC test time/value several times that of analog chips) × Huafeng's SoC revenue starting from zero — if the domestic SoC tester market reaches RMB 7–12 billion per year in 2027–2028 (third-party estimate, order-of-magnitude reference) and Huafeng captures 5–15% share, that implies annual SoC revenue of RMB 350 million – 1.8 billion. Key decoupling caveat: the AI/HBM increment driving the industry's +55% lands in the duopolists' home turf; Huafeng's direct AI exposure opens only when the 8600 delivers — linearly extrapolating "record industry → record company" will systematically overestimate the transmission of the upcycle.
Company positioning within the industry: Absolute domestic leader in analog/mixed-signal/power testers plus a top international player. Share figures must be presented side by side: domestic analog segment share of 40%+ (third-party basis) to 70% (company earnings-call basis, STS8200 only) — the gap stems from statistical scope (all analog vs. the 8200 platform); share of China's tester market on an all-in basis ~5.5% (our estimate: domestic main-business revenue RMB 1.248 billion ÷ China market ~RMB 22.5 billion), global revenue share ~1.2%. Share trend is rising (Huafeng + Changchuan combined 2025 revenue +46%, faster than the China market overall). Moat = installed base + qualification barriers + R&D intensity + service network; weaknesses = smaller AI-mainstream exposure than the duopoly and Changchuan, overseas revenue only 6.9%, scale gap vs. Changchuan (3.9x) — positioned as a niche market leader transitioning to a SoC challenger; the ceiling depends on whether the 8600 can replicate the substitution path of the analog segment.
Testers are an order-driven equipment business, with revenue recognition lagging orders by 1–2 quarters; no total backlog disclosure and no book-to-bill — three balance-sheet line items are the only trackable order proxies:
| Item (RMB 100M) | End-2023 | End-2024 | End-2025 | End-2026Q3 | Signal interpretation |
|---|---|---|---|---|---|
| Contract liabilities (advances) | 0.28 | 0.56 | 0.78 | 1.88 (+142% vs. start of year) | Order build-up accelerating — per company: "increased orders, corresponding increase in advances" |
| Inventory | 1.42 | 1.77 | 3.00 | 5.40 (+80.4%) | Strategic stocking + supply chain switch + delivery assurance (raw materials FY2025 +112.6%) |
| Accounts receivable | ~2.4 | ~3.3 | 5.54 | 8.29 (+49.8%) | Growth above revenue for two consecutive years — extended payment terms or customer-mix shift, unexplained |
The combination of all three items jumping in the same direction historically appears on the eve of delivery peaks (the 2020–2021 pattern was similar); but beware the flip side: AR + inventory combined have reached 101% of nine-month revenue, and OCF/deducted-non-recurring profit is 0.39 — if revenue decelerates in 2027 while these items keep growing on inertia, "stocking" will become "pile-up" and OCF will approach zero. Tracking discipline: ① Annual-report contract liabilities ≥ RMB 150M or at new highs = cycle intact; < RMB 120M = order build-up falsified; ② rising share of shipped goods/finished goods within inventory detail = positive signal of deliveries awaiting acceptance; ③ OCF/deducted-non-recurring ≥ 0.35 as the pass line; ④ whether the order-visibility horizon in investor-meeting notes can extend beyond 2027-03 (management basis; can be narrowed at any time; evidentiary weight below accounting items). The company discloses no quantitative backlog data and has given no earnings guidance for many consecutive years — tracking relies entirely on the above proxies and periodic reports.
Verdict: Neutral (wait-and-see), confidence 0.55, horizon 12–18 months. Huafeng MeasureTech is a scarce A-share, globally ranked niche semiconductor equipment leader: genuine orders, top-tier global profitability, net-cash balance sheet; but at the current price of RMB 231.20, the market already prices in sell-side consensus's two-year high growth; baseline fair value is RMB 197–230, weighted expected value ~RMB 215, with slightly negative odds and an extremely wide distribution (bear −58% to −68% / bull +38% to +63%). Strategy: do not chase, do not short — the quality-against-positioning hedge signals (RMB 250 buyback ceiling / RMB 329 institutional transfer price / RMB 362 insider cost) rule out the case for buying on deep dips, but the 2027–28 cycle-top risk and the unproven 8600 rule out chasing; wait for two entry signals — price falling below RMB 200 (near the lower bound of baseline fair value) or evidence upgrade (Q4 order-to-revenue conversion ≥ +45%, 8600 volume orders, renewed guidance hikes by the duopoly).
Risk and catalyst calendar:
Upside catalysts: 2026 annual report Q4 order-to-revenue conversion materializing (Q4 revenue ≥ RMB 590M, full-year deducted-non-recurring profit ≥ RMB 700M); STS8600 volume order/deployment announcements; rapid buyback execution; Advantest's third guidance hike on 2027-01; spillover from domestic compute-chip makers' capacity expansion. Downside triggers: Q4 revenue < +30% or contract liabilities < RMB 120M; guidance cuts by Advantest/Teradyne or North American cloud capex downgrades; new controlling-shareholder reduction plans or concentrated selling after lockup expiry; AR/inventory impairments and fair-value swings amplifying downside to net profit; game-theoretic disruption if the convertible bond's reset clause triggers again after 2027-01-12.
(All prices in this report are based on the 2026-11-11 closing price of RMB 231.20; all valuation estimates use this frozen anchor: market cap RMB 46.498 billion, total shares 201.12 million. Financial data are as of the 2026 Q3 report; balance-sheet stock figures are as of 2026-09-30.)